Difficulty: Medium
Average Score: 72%
Practice
A 5-year-old child, recently diagnosed with ileocecal Burkitt lymphoma; lab investigations reveal: serum uric acid 12 mg/dl, serum sodium, 145 meq/dl; serum potassium, 4.5 meq/dl; serum phosphate 4.4 meq/dl; serum calcium, 8.9 mg/dl; blood urea, 22 mg/dl; serum creatinine, 0.8 mg/dl. Of the following, the MOST effective treatment is
Correct answer
D
Rationale
In this scenario, the most effective treatment for the 5-year-old child with ileocecal Burkitt lymphoma and elevated serum uric acid levels is option D, recombinant urate oxidase. This is because the child is at risk for tumor lysis syndrome (TLS), a potential complication of cancer treatment characterized by metabolic abnormalities like hyperuricemia. Recombinant urate oxidase helps convert uric acid into a more soluble form, preventing uric acid crystallization and subsequent kidney damage.
Option A, excessive hydration, is not the most effective treatment as it may dilute the uric acid concentration but does not address the underlying issue of converting uric acid into a more soluble form. Option B, sodium bicarbonate, is used to alkalinize the urine in TLS but does not directly lower uric acid levels. Option C, xanthine oxidase inhibitor, is used in chronic hyperuricemia but may not be as effective in acute TLS.
Educationally, understanding the pathophysiology of TLS and the role of recombinant urate oxidase in managing hyperuricemia can help healthcare providers make informed treatment decisions in pediatric oncology cases. This case highlights the importance of prompt and appropriate management to prevent complications associated with TLS in pediatric patients with malignancies.
Option A, excessive hydration, is not the most effective treatment as it may dilute the uric acid concentration but does not address the underlying issue of converting uric acid into a more soluble form. Option B, sodium bicarbonate, is used to alkalinize the urine in TLS but does not directly lower uric acid levels. Option C, xanthine oxidase inhibitor, is used in chronic hyperuricemia but may not be as effective in acute TLS.
Educationally, understanding the pathophysiology of TLS and the role of recombinant urate oxidase in managing hyperuricemia can help healthcare providers make informed treatment decisions in pediatric oncology cases. This case highlights the importance of prompt and appropriate management to prevent complications associated with TLS in pediatric patients with malignancies.